that leaders in critical care nephrology have confirmed clinical utility of the company's glomerular filtration biomarker penKidŽ for early diagnosis, exclusion and monitoring of acute kidney injury (AKI). Data from prospective, observational studies presented at the 24th International Conference on Advances in Critical Care Nephrology (AKI & CRRT; 26 Feb-1 March, 2019) in San Diego demonstrate that penKidŽ is suitable to guide treatment decisions at ICUs and EDs.

At the AKI & CRRT conference, Prof. Matthieu Legrand (Critical Care Medicine & Burn Unit at Hôpital Lariboisičre Paris, France) reported results from a sub-study of the PRONOburn cohort that enrolled 113 burn patients admitted to burn intensive care units (ICUs). High penKidŽ levels at admission (> 80 pmol/L) were sufficient to predict acute kidney injury (AKI) even when other indicators such as the SOFA score gave no sufficient information (p<0.001). In sepsis patients, enrolled in the FROG-ICU and AdrenOSS-1 cohorts, including more than 1,100 patients, elevated penKidŽ plasma levels identified sub-AKI while creatinine values remained normal (1 out of 4 patients). Sub-AKI was associated with worse outcomes.

Peer-reviewed data [1] on the biological variation of four AKI biomarker testsin patients with stable heart disease presented by Dr. Alan Wu (UCLA, San Francisco) demonstrated that penKidŽ is best suited for early diagnosis of renal insufficiency in clinical practice. Data from 85 individuals enrolled in the Valsartan Heart Failure Trial (Val-HeFT) support that penKidŽ testing would be of value in managing patients in EDs and ICUs. Commenting on the results, key opinion leaders suggested to add penKidŽ measurements to AKI routine testing for triaging and monitoring, which today only allows delayed information using available biomarkers.

"The biovariability of a biomarker is a key attribute, but not tested for many of the novel kidney markers. penKidŽ shows a low variability  allowing information with the first measurement," said Dr. Wu. "penKidŽ has a huge value to rule out patients in EDs," confirmed Prof. Salvatore Di Somma, Head of Emergency Medicine Sant'Andrea Hospital, Rome, Italy. sphingotec showed data from pilot routine testing, which has already begun at undisclosed ICUs and EDs in Germany. Study leaders confirmed that triaging will be supported by penKidŽ information, because the marker can rule out AKI as BNP rules out Heart Failure. David Bruno, Director of the University of Maryland Transplant Surgery Program announced starting tests with penKidŽ to predict graft function recovery in kidney transplantation.

Plasma penKidŽ is a surrogate marker for disturbed renal glomerular filtration rate (GFR), which reflects kidney function. Previous studies on more than 30,000 critically ill patients admitted to EDs or ICUs with congestive heart failure [2] or sepsis [3] demonstrated that penKidŽ levels change dynamically with the actual kidney function independently from comorbidities or inflammation [4]. penKidŽ levels rise up to 48 hours prior to those of creatinine preceding kidney injury (AKI), which affects about 25 percent of patients admitted to ICUs.

By the end of H1/2019, sphingotec will launch a penKidŽ point-of-care (POC) test on its fully automated Nexus IB10 POC testing platform for use in EDs and ICUs. The platform allows measurement of up to five critical care biomarker tests in one run within 20 minutes without any sample preparation.

About sphingotec GmbH: sphingotec GmbH (Hennigsdorf, Germany) is developing and marketing innovative biomarkers such as penKidŽ and bio-ADMŽ for prediction, diagnosis and therapy monitoring of AKI, congestive heart failure and septic shock, as well as the Nexus IB10 POC testing immunoassay platform acquired from Samsung-subsidiary Nexus Dx Inc. in May 2018. The company, founded by Dr. Andreas Bergmann in 2002, in addition is developing a pipeline of novel biomarkers which can predict the risks of obesity, breast cancer and cardiovascular diseases.

About International Conference on Advances in Critical Care Nephrology: The AKI & CRRT conference provides a comprehensive review of advances in clinical care, research and technology in critical care medicine with a focus on the kidney and renal support techniques.

About penKidŽ: penKidŽ is the very first functional kidney marker that works in blood. penKidŽ is independent from comorbidities and inflammation and provides timely information about the changing kidney function in critically ill patients. sphingotestŽ penKidŽ is non-inferior to the gold standard in vivo measurement of glomerular filtration rate (GFR). These features enable physicians to diagnose and closely monitor worsening and improving kidney function in critically ill patients.

View original content:http://www.prnewswire.com/news-releases/sphingotec-announces-new-data-on-the-kidney-function-marker-pro-enkephalin-penkid-presented-at-24th-international-conference-on-advances-in-critical-care-nephrology-300812617.html

SOURCE sphingotec

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.

Your comments are automatically posted once they are submitted. All comments are however constantly reviewed for spam and irrelevant material (such as product or personal advertisements, email addresses, telephone numbers and website address). Such insertions do not conform to our policy and 'Terms of Use' and are either deleted or edited and republished.Please keep your comments brief and relevant.This section may also have questions seeking help. If you have the information you are welcome to respond, but please ensure that the information so provided is genuine and not misleading.

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.Full Disclaimer